DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Deep Vein Thrombosis, offering comprehensive insights into the Deep Vein Thrombosis revenue trends, prevalence, and treatment landscape. The report delves into key Deep Vein Thrombosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Deep Vein Thrombosis therapies. Additionally, we cover the landscape of Deep Vein Thrombosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Deep Vein Thrombosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Deep Vein Thrombosis space.
To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast
Some of the key facts of the Deep Vein Thrombosis Market Report:
-
The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
-
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
-
The Deep Vein Thrombosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.
-
The Centers for Disease Control and Prevention (CDC) (2023) reports that while the exact number of individuals affected by DVT or PE is uncertain, it is estimated that up to 900,000 people may be impacted annually in the United States.
-
According to Waheed et al. (2023), over 200,000 individuals in the United States develop venous thrombosis each year, with 50,000 cases complicated by pulmonary embolism. The annual incidence of DVT is 80 cases per 100,000 people, with a prevalence of lower limb DVT at 1 case per 1,000 population.
-
Waheed et al. (2023) noted that deep vein thrombosis is uncommon in children, and the risk significantly rises with age, with most cases occurring in individuals over 40.
-
The CDC (2023) states that about 33% of individuals with DVT or PE will experience a recurrence within 10 years.
Deep Vein Thrombosis Overview
Deep vein thrombosis (DVT) is a condition where a blood clot forms in a deep vein, typically in the legs. This can cause pain, swelling, and discomfort. DVT is dangerous because the clot can break loose and travel to the lungs, leading to a life-threatening condition called pulmonary embolism. Risk factors include prolonged immobility, surgery, certain medications, and medical conditions that affect blood clotting. Treatment usually involves blood thinners to prevent clot growth and reduce the risk of complications. Early detection and treatment are critical to managing DVT effectively.
Get a Free sample for the Deep Vein Thrombosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
Deep Vein Thrombosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Deep Vein Thrombosis Epidemiology Segmentation:
The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalent Cases of DVT in the 7MM
-
Diagnosed Prevalent Cases of DVT in the 7MM
-
Age-specific Cases of DVT in the 7MM
-
Total Treated Cases of DVT in the 7MM
Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast
Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Deep Vein Thrombosis Therapies and Key Companies
-
Rivaroxaban: Bayer
-
innohep®: LEO Pharma
-
ThromboView: Agen Biomedical
-
Apixaban: Bristol-Myers Squibb
-
SanOrg34006: Sanofi
-
Tinzaparin: Ottawa Hospital Research Institute
-
edoxaban tosylate: Daiichi Sankyo
-
r-Hirudin: MinaPharm Pharmaceuticals
-
Fondaparinux sodium: GlaxoSmithKline
-
PD 0348292: Pfizer
-
Dalteparin: Anthos Therapeutics, Inc.
Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Landscape
Deep Vein Thrombosis Market Strengths
-
The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT.
-
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of DVT.
Deep Vein Thrombosis Market Opportunities
-
New therapeutic options are needed to address the unmet need for effective and curative therapies for DVT. This has created an opportunity for key players to develop novel therapies targeted towards this indication.
Scope of the Deep Vein Thrombosis Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
-
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
-
Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
-
Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement
To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Deep Vein Thrombosis Market Report Introduction
2. Executive Summary for Deep Vein Thrombosis
3. SWOT analysis of Deep Vein Thrombosis
4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance
5. Deep Vein Thrombosis Market Overview at a Glance
6. Deep Vein Thrombosis Disease Background and Overview
7. Deep Vein Thrombosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Deep Vein Thrombosis
9. Deep Vein Thrombosis Current Treatment and Medical Practices
10. Deep Vein Thrombosis Unmet Needs
11. Deep Vein Thrombosis Emerging Therapies
12. Deep Vein Thrombosis Market Outlook
13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)
14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies
15. Deep Vein Thrombosis Market Drivers
16. Deep Vein Thrombosis Market Barriers
17. Deep Vein Thrombosis Appendix
18. Deep Vein Thrombosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer